圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688289 圣湘生物

已收盘 07-23 15:00:00

{"stockData":{"symbol":"688289","market":"SH","secType":"STK","nameCN":"圣湘生物","latestPrice":19.01,"timestamp":1721718000000,"preClose":19.37,"halted":0,"volume":3997356,"delay":0,"floatShares":583000000,"shares":583000000,"eps":0.6595,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.36,"latestTime":"07-23 15:00:00","open":19.34,"high":19.39,"low":19.01,"amount":76705500,"amplitude":0.0196,"askPrice":19.03,"askSize":594,"bidPrice":19.01,"bidSize":136,"shortable":0,"etf":0,"ttmEps":0.6595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721784600000},"adr":0,"adjPreClose":19.37,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":21.31,"lowLimit":17.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":583388006,"pbRate":1.52,"roa":"--","roe":"1.12%","epsLYR":0.62,"committee":-0.483037,"marketValue":11090000000,"floatMarketCap":11090000000,"peRate":28.824867,"changeRate":-0.0186,"turnoverRate":0.0069,"status":1,"afterMarket":{"amount":0,"volume":0,"close":19.01,"buyVolume":0,"sellVolume":0,"time":1721720037153,"indexStatus":"已收盘 07-23 15:30:00","preClose":19.37}},"requestUrl":"/m/hq/s/688289/tweets","defaultTab":"tweets","newsList":[{"id":"2453705607","title":"肝炎概念盘中跳水，圣湘生物跌0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453705607","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453705607?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:28","pubTimestamp":1721716088,"startTime":"0","endTime":"0","summary":"07月23日，肝炎概念盘中跳水，截至14点28分，肝炎概念整体指数下跌2.03%，报738.410点。从个股上来看，该概念的成分股中，圣湘生物跌0.98%，华仁药业、赛升药业、热景生物跌幅居前。从资金上来看，截止发稿，肝炎概念概念主力净流入为-1.15亿，其中科伦药业受到资金热捧，主力净流入4372.15万；拉长时间线来看，该板块近20日主力资金净流入-17.66亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723142808af9391d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723142808af9391d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2453735788","title":"北向资金7月19日净买入圣湘生物60.05万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2453735788","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453735788?lang=zh_cn&edition=full","pubTime":"2024-07-22 09:30","pubTimestamp":1721611839,"startTime":"0","endTime":"0","summary":"7月19日, 北向资金增持圣湘生物60.05万股，连续3日增持。截止当日收盘，沪股通共持有圣湘生物859.62万股，占流通股1.47%。沪股通增持金额前五个股分别为XD江淮汽、赤峰黄金、中金黄金、北汽蓝谷、伊利股份。圣湘生物近5个交易日上涨6.69%，沪股通累计增持48.47万股；近20个交易日上涨2.67%，沪股通累计增持27.59万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407220935289edd4fac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407220935289edd4fac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2452512604","title":"圣湘生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2452512604","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452512604?lang=zh_cn&edition=full","pubTime":"2024-07-18 13:06","pubTimestamp":1721279209,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日圣湘生物科技股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来圣湘生物科技股份有限公司新申请注册商标11件，截止目前公司共持有注册商标708件，另有41件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800025437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2452140096","title":"西南证券发布圣湘生物研报，乘风而起，加速分子诊断赛道布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2452140096","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452140096?lang=zh_cn&edition=full","pubTime":"2024-07-18 11:32","pubTimestamp":1721273520,"startTime":"0","endTime":"0","summary":"西南证券07月18日发布圣湘生物（688289.SH，最新价：18.21元）研报称：1）疫情催生分子诊断需求，未来有望迎来高速增长；2）呼吸道检测需求旺盛，联检产品持续升温；3）助力2030年两大疾病“病毒性肝炎”和“宫颈癌”消除计划。风险提示：行业竞争加剧风险、销售收入季节性波动风险、研发进展不及预期风险。AI点评：圣湘生物近一个月获得2份券商研报关注，买入2家，平均目标价为20.44元，与最新价18.21元相比，高2.23元，目标均价涨幅12.25%。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181134589f6176b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407181134589f6176b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600369","688289","BK0183","BK0276","BK0188","BK0239","BK0028","BK0012"],"gpt_icon":0},{"id":"2452130925","title":"圣湘生物(688289.SH)实控人提议公司中期分红：每10股派2.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452130925","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452130925?lang=zh_cn&edition=full","pubTime":"2024-07-17 19:24","pubTimestamp":1721215466,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣湘生物 发布公告，公司于近日收到公司实际控制人兼董事长戴立忠先生出具的《关于提议中期分红、注销部分已回购股份暨落实公司2024年度“提质增效重回报”行动方案的函》。戴立忠先生承诺将在公司董事会及股东大会审议该等事项时投赞成票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2452130756","title":"圣湘生物：实际控制人兼董事长提议中期分红并注销部分已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452130756","media":"财通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452130756?lang=zh_cn&edition=full","pubTime":"2024-07-17 19:12","pubTimestamp":1721214720,"startTime":"0","endTime":"0","summary":"圣湘生物公告，公司实际控制人兼董事长戴立忠先生提议，在符合相关规定的前提下，公司实施2024年度中期分红方案，每10股派发现金红利2.50元（含税），并注销存放于回购专用证券账户的100万股以提升每股收益。上述提议需经股东大会审议通过，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071719130695ce4322&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071719130695ce4322&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2451189135","title":"圣湘生物新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2451189135","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451189135?lang=zh_cn&edition=full","pubTime":"2024-07-13 13:01","pubTimestamp":1720846866,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日圣湘生物科技股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来圣湘生物科技股份有限公司新申请注册商标8件，截止目前公司共持有注册商标708件，另有38件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071300013501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2450217258","title":"“创新+服务”双轮驱动业绩强劲增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2450217258","media":"湖南日报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450217258?lang=zh_cn&edition=full","pubTime":"2024-07-11 06:19","pubTimestamp":1720649989,"startTime":"0","endTime":"0","summary":"今年上半年，圣湘生物继续以“创新+服务”双轮驱动，稳步推进平台化、国际化战略，进一步巩固和提升在体外诊断领域的技术及市场优势，展现出强劲的增长潜力。核心领域技术取得突破性进展2024年第一季度，圣湘生物业绩大幅增长。继2024年首季“开门红”后，圣湘生物半年度业绩继续以高增长惊艳亮相。据悉，今年上半年呼吸道类产品营业收入已与去年全年总额基本持平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071106195795a1b090&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071106195795a1b090&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2450882988","title":"圣湘生物（688289）7月9日主力资金净卖出57.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450882988","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450882988?lang=zh_cn&edition=full","pubTime":"2024-07-10 08:25","pubTimestamp":1720571110,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月9日收盘，圣湘生物报收于17.17元，下跌0.52%，换手率0.57%，成交量3.35万手，成交额5729.0万元。近5日资金流向一览见下表：圣湘生物融资融券信息显示，融资方面，当日融资买入452.56万元，融资偿还174.77万元，融资净买入277.79万元。圣湘生物主营业务：研发、生产、销售体外诊断试剂及仪器、提供检测服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000013449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2449406034","title":"圣湘生物（688289）7月4日主力资金净买入205.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449406034","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449406034?lang=zh_cn&edition=full","pubTime":"2024-07-05 08:12","pubTimestamp":1720138346,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月4日收盘，圣湘生物报收于17.18元，上涨1.72%，换手率0.94%，成交量5.56万手，成交额9590.17万元。近5日资金流向一览见下表：圣湘生物融资融券信息显示，融资方面，当日融资买入521.17万元，融资偿还576.14万元，融资净偿还54.97万元。圣湘生物主营业务：研发、生产、销售体外诊断试剂及仪器、提供检测服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500010389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2449403086","title":"圣湘生物获开源证券买入评级，2024年上半年业绩亮眼，多领域逐步进入放量期","url":"https://stock-news.laohu8.com/highlight/detail?id=2449403086","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449403086?lang=zh_cn&edition=full","pubTime":"2024-07-05 06:57","pubTimestamp":1720133872,"startTime":"0","endTime":"0","summary":"7月5日，圣湘生物获开源证券买入评级，近一个月圣湘生物获得2份研报关注。研报预计公司2024上半年预计实现营收7.10亿元，同比增长66%，归母净利润1.50-1.65亿元，同比增长64%-80%，扣非净利润1.20-1.30亿元，同比增长285%-317%。同时，预计公司2024-2026年归母净利润分别为3.16/4.41/6.16亿元。此外，该公司深入布局多领域，持续实施创新驱动战略，强化平台化、国际化战略打造，内生驱动与外延增长齐驱并进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070507032895782452&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070507032895782452&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","161027"],"gpt_icon":0},{"id":"2449408360","title":"开源证券给予圣湘生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2449408360","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449408360?lang=zh_cn&edition=full","pubTime":"2024-07-05 06:42","pubTimestamp":1720132920,"startTime":"0","endTime":"0","summary":"开源证券07月04日发布研报称，给予圣湘生物（688289.SH，最新价：17.18元）买入评级。评级理由主要包括：1）持续专注深耕分子诊断，内生增长动力强劲，后市可期；2）多领域关键赛道布局加速，外延驱动平台型IVD企业持续成长。风险提示：产品推广不及预期、政策变化风险、集采影响毛利率。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407050644099f061ce8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407050644099f061ce8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","161027"],"gpt_icon":0},{"id":"2448415926","title":"圣湘生物(688289)呼吸道检测业务“淡季不淡”得验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2448415926","media":"国投证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448415926?lang=zh_cn&edition=full","pubTime":"2024-07-04 15:16","pubTimestamp":1720077388,"startTime":"0","endTime":"0","summary":"二季度呼吸道检测业务保持了较高景气，“淡季不淡”得验证。我们曾在2024年5月6日发布的研报《再谈呼吸道检测：看好行业长期景气度》中提到了“呼吸道检测行业‘淡旺季’分布呈‘四六开’规律”，行业存在“淡季不淡”的现象，从目前行业层面的高频数据以及企业层面的经营情况来看，此判断得到了较好印证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070415301195739384&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070415301195739384&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","BK0239"],"gpt_icon":0},{"id":"2448415924","title":"国投证券给予圣湘生物买入评级 呼吸道检测业务“淡季不淡”得验证 目标价格为20.44元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448415924","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448415924?lang=zh_cn&edition=full","pubTime":"2024-07-04 15:02","pubTimestamp":1720076543,"startTime":"0","endTime":"0","summary":"国投证券07月04日发布研报称，给予圣湘生物（688289.SH，最新价：17.21元）买入评级，目标价格为20.44元。评级理由主要包括：1）事件：圣湘生物发布2024年半年度业绩预告；2）二季度呼吸道检测业务保持了较高景气，“淡季不淡”得验证；3）产品+品牌，实践证明公司能在激烈竞争中占据主导市场地位。风险提示：公司业务拓展不及预期的风险、行业政策变动风险、行业竞争进一步加剧的风险。文章来源：每日经济新闻原标题：国投证券给予圣湘生物买入评级，呼吸道检测业务“淡季不淡”得验证，目标价格为20.44元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041519109f018af1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041519109f018af1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688289","161027"],"gpt_icon":0},{"id":"2448041812","title":"圣湘生物获国投证券买入评级，6个月目标价为20.44元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448041812","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448041812?lang=zh_cn&edition=full","pubTime":"2024-07-04 14:57","pubTimestamp":1720076273,"startTime":"0","endTime":"0","summary":"7月4日，圣湘生物获国投证券买入评级，近一个月圣湘生物获得1份研报关注。研报预计公司2024-2026年营业收入分别同比增长51.5%、32.2%、26.7%；归母净利润分别同比增长-5.5%、34.5%、48.4%，成长性突出。另外，行业竞争激烈，但实践证明圣湘生物依然凭借合理的标靶和平台设计、出色的产品性能以及优秀的销售能力占据绝对主导的市场地位。因此，研报维持给予买入-A的投资评级，6个月目标价20.44元，相当于2024年35倍的动态市盈率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041503159f017492&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407041503159f017492&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161027","688289"],"gpt_icon":0},{"id":"2448639044","title":"圣湘生物7月3日转融通出借成交22700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448639044","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448639044?lang=zh_cn&edition=full","pubTime":"2024-07-04 09:14","pubTimestamp":1720055683,"startTime":"0","endTime":"0","summary":"根据上交所网站显示，7月3日，圣湘生物转融通出借成交22700股，期限为8天。据了解，转融通是指证券金融公司将自有或者依法筹集的资金和证券出借给证券公司，以供其办理融资融券业务的经营活动。上交所接受借入人借入申报的时间为每个交易日 9:15 至 11:30、13:00 至 15:10。公开资料显示，圣湘生物法人代表为戴立忠，公司注册资本5.88亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040914469effa440&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407040914469effa440&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688289"],"gpt_icon":0},{"id":"2448485614","title":"圣湘生物：预计2024年1-6月归属净利润盈利1.5亿元至1.65亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448485614","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448485614?lang=zh_cn&edition=full","pubTime":"2024-07-03 22:00","pubTimestamp":1720015231,"startTime":"0","endTime":"0","summary":"证券之星消息，圣湘生物发布业绩预告，预计2024年1-6月归属净利润盈利1.5亿元至1.65亿元。圣湘生物2024年一季报显示，公司主营收入3.91亿元，同比上升100.31%；归母净利润8102.47万元，同比上升35.01%；扣非净利润7375.57万元，同比上升1962.06%；负债率13.91%，投资收益-1688.85万元，财务费用-1703.1万元，毛利率81.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300047446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289"],"gpt_icon":0},{"id":"2448107535","title":"“创新+服务”双轮驱动，圣湘生物上半年扣非净利润预增约300%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448107535","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448107535?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:48","pubTimestamp":1720010919,"startTime":"0","endTime":"0","summary":"7月3日晚间，圣湘生物披露业绩预告，预计上半年实现营业收入7.1亿元，同比增长66%；归母净利润1.5-1.65亿元，同比增长64%-80%；扣非净利润为1.2-1.3亿元，同比增长285%-317%。今年上半年，圣湘生物继续以“创新+服务”双轮驱动，稳步推进平台化、国际化战略，进一步巩固和提升在体外诊断领域的技术及市场优势，展现出强劲的增长潜力。据悉，今年上半年圣湘生物呼吸道类产品营业收入已与去年全年总额基本持平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024070300044213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688289"],"gpt_icon":0},{"id":"2448037101","title":"圣湘生物(688289.SH)发预增，预计净利润1.5亿元到1.65亿元，同比增长64%到80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448037101","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448037101?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:10","pubTimestamp":1720008648,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣湘生物(688289.SH)披露2024年半年度业绩预告，公司预计2024年半年度实现归属于母公司所有者的净利润1.5亿元到1.65亿元，同比增长64%到80%;预计2024年半年度实现归属于母公司所有者的扣除非经常性损益的净利润1.2亿元到1.3亿元，同比增长285%到317%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688289"],"gpt_icon":0},{"id":"2448101401","title":"圣湘生物(688289.SH)获得政府补助4699.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448101401","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448101401?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:08","pubTimestamp":1720008510,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣湘生物(688289.SH)公告，公司于近日收到湖南湘江新区管理委员会商务和市场监管局拨付的产业扶持资金人民币4699.80万元，该笔补助资金系与收益相关的政府补助，公司已实际收到款项并计入当年损益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688289"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-28","address":"湖南省长沙市岳麓区高新技术产业开发区麓松路680号","stockEarnings":[{"period":"1week","weight":0.1151},{"period":"1month","weight":0.0573},{"period":"3month","weight":0.0585},{"period":"6month","weight":0.0965},{"period":"1year","weight":0.1262},{"period":"ytd","weight":0.0017}],"companyName":"圣湘生物科技股份有限公司","boardCode":"AI0027","perCapita":"28482股","boardName":"医药制造业","registeredCapital":"58338万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":"　　圣湘生物科技股份有限公司的主营业务为以自主创新基因技术为核心，集诊断试剂和仪器的研发、生产、销售，以及第三方医学检验服务于一体的体外诊断整体解决方案，其主要产品为病毒性肝炎系列产品、生殖道感染与遗传系列产品、儿科感染系列产品、呼吸道感染系列产品、核酸血液筛查系列产品、科研、公共卫生、动物疫病系列产品、核酸提取系列产品、生化系列产品、全自动核酸检测反应体系构建系列产品、POCT移动分子诊断系统系列产品、荧光PCR检测分析软件、第三方医学检验服务、科研服务。","serverTime":1721737446867,"listedPrice":50.48,"stockholders":"20482人(较上一季度减少6.70%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣湘生物,688289,圣湘生物股票,圣湘生物股票老虎,圣湘生物股票老虎国际,圣湘生物行情,圣湘生物股票行情,圣湘生物股价,圣湘生物股市,圣湘生物股票价格,圣湘生物股票交易,圣湘生物股票购买,圣湘生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣湘生物(688289)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣湘生物(688289)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}